At variance, in vitro studies with ERβ agonists have suggested that they could inhibit the proliferation of melanoma cells harboring the NRAS mutation, an important gene of the RAS family [88], indicating that ERβ might impair melanoma onset through inhibition of the PI3K/Akt pathway. This evidence concerns the gene AKT1 and melanoma.